Physician profile
David B Wilkinson
NPI 1609841659
$9,381.52
in general payments reported to CMS, 2019-2025
7 companies · $4,820 in 2025
The $4,820 reported for 2025 was more than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2022: $230 · 2023: $2,058 · 2024: $2,048 · 2025: $4,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,060 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,050 · Food and Beverage: $761 · Education: $55.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,060.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,050.00 |
| Food and Beverage | $761.30 |
| Education | $55.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $3,990.08 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $3,206.97 | 2019-2025 | Soliris, Ultomiris |
| Ucb, INC. | $1,744.16 | 2022-2025 | Zilbrysq, Rystiggo |
| Genentech, INC. | $146.02 | 2023 | Evrysdi |
| Tanabe Pharma America, INC. | $100.00 | 2019 | |
| Biogen, INC. | $97.43 | 2024 | Spinraza |
| Eisai INC. | $96.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.